title: Multimodal treatment of patients with minor salivary gland cancer in the case of recurrent disease.
abstract: BACKGROUND
  Our aim in this study was to identify prognostic factors and the optimal therapeutic management in patients with minor salivary gland carcinomas.
  
  
  METHODS
  Overall and disease-free survival and overall survival after recurrence in patients with adenoidcystic carcinoma (n = 25), mucoepidermoid carcinoma (n = 8), adenocarcinoma (n = 5), carcinoma ex pleomorphic adenoma (n = 4), and others (n = 5) were correlated to clinical data.
  
  
  RESULTS
  Overall survival correlated to treatment modality (p = .039) and T classification (p = .003), whereas prolonged disease-free interval correlated to treatment (p < .001) and T classification (p = .009). Overall survival after recurrence correlated to treatment of recurrence (p = .006) and initial T classification (p = .02). Multivariate analysis showed that overall survival after recurrence correlated to treatment of recurrence (p = .019) and initial T classification (p = 0.019). T classification was a prognostic factor for overall survival (p = .002) and disease-free interval (p = .002).
  
  
  CONCLUSIONS
  The initial tumor classification is a clinical predictor for patients' overall and disease-free survival and overall survival after recurrence. Multimodal treatment significantly improves patients' overall survival.
authors.affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
authors.forename: Boban M
authors.initials: BM
authors.lastname: Erovic
authors.forename: Christian
authors.initials: C
authors.lastname: Schopper
authors.forename: Johannes
authors.initials: J
authors.lastname: Pammer
authors.forename: Laurenz
authors.initials: L
authors.lastname: Vormittag
authors.forename: Amir
authors.initials: A
authors.lastname: Maleki
authors.forename: Markus
authors.initials: M
authors.lastname: Brunner
authors.forename: Gregor
authors.initials: G
authors.lastname: Heiduschka
authors.forename: Matthaeus Ch
authors.initials: MCh
authors.lastname: Grasl
authors.forename: Dietmar
authors.initials: D
authors.lastname: Thurnher
mesh_terms: D008949:Adenoma, Pleomorphic / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D003528:Carcinoma, Adenoid Cystic / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018277:Carcinoma, Mucoepidermoid / Q000401:mortality / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D012470:Salivary Glands, Minor / Q000473:pathology* / Q000601:surgery; D016019:Survival Analysis; D016896:Treatment Outcome